We recommend ordering the new Illumina DNA/RNA UD Indexes Sets A-D (20091654, 20091656, 20091658, 20091660). The IDT for Illumina DNA/RNA UD Indexes Sets A-D (20027213, 20027214,20042666, 20042667) are obsolete and the last order date is January 30, 2025, as announced in PON2023-1440.
TruSight Hereditary Cancer Panel
Expert-defined content targeting 113 genes associated with genetic cancer risk predisposition.
Read More...
Index Adapters
Reagents
Total:
Product Highlights
The TruSight Hereditary Cancer Panel content was selected based on feedback from key opinion leaders on genetic risk assessment research.
- Includes 10,341 probes that target 113 genes related to cancer predisposition research.
- TruSight Hereditary Cancer Panel includes 125 SNPs. Of these, 48 are ID SNPs and 77 are used for polygenic risk scoring (PRS) research.
- In combination with Illumina DNA Prep with Enrichment, TruSight Hereditary Cancer Panel enables genetic labs to prepare hybrid capture sequencing libraries in 6.5 hours with limited hands on time of ~2 hours.
- Accommodates flexible workflows and is compatible with different sources of samples such as genomic DNA, saliva (Oragene tubes) or blood (Flex Lysis Reagent). It is compatible with all Illumina benchtop sequencers, and allows for maximum flexibility for batching from 2 to 256 samples.
TruSight Hereditary Cancer Panel was created as a modular panel that uses Illumina DNA Prep with Enrichment for library preparation.
Indexes are available for up to 384 samples to allow for flexible batch sizes and scalability across all Illumina benchtop sequencers (iSeq 100, MiSeq, MiniSeq, and NextSeq).
The Illumina DNA Prep with Enrichment library prep workflow uses enzyme-based DNA fragmentation, removing the instrument cost and need for mechanical fragmentation. Illumina DNA Prep with Enrichment has been qualified with multiple automation systems to allow for a user-friendly workflow.
Frequently Purchased Together
Specifications
Product Comparison
| TruSight Hereditary Cancer Panel | TruSight Cancer | AmpliSeq for Illumina BRCA Panel | |
|---|---|---|---|
| Assay Time | ~6.5 hours | 1.5 days | 5 hours (library prep only; doesn't include library quantification, normalization, or pooling time) |
| Content Specifications | Targets 113 cancer risk-associated genes | Fixed set of probes that enrich for 94 genes and 284 SNPs associated with common and rare cancers. | Exonic regions and the flanking intronic sequences of the BRCA1 and BRCA2 |
| Hands-On Time | 2 hours | 5 hours | < 1.5 hours |
| Input Quantity | 50 ng | 50 ng DNA | 1–100 ng (10 ng recommended per pool) |
| Mechanism of Action | Bead-bound transposomes and hybrid-capture chemistry | Multiplex PCR | |
| Method | Target Enrichment, Target Enrichment, Targeted DNA Sequencing | Target Enrichment, Target Enrichment, Targeted DNA Sequencing | Amplicon Sequencing, Targeted DNA Sequencing |
| Nucleic Acid Type | DNA | DNA | DNA |
| Technology | Sequencing | Sequencing | Sequencing |
Product Literature
Understanding the Polygenicity of Cancer.
icommunity_articles | PDF 4 MB
Data Sheet | HTML | 7 versions
Data Sheet | HTML | 5 versions
Analyze germline CNVs with TruSight Hereditary Cancer Panel
Technical Note | PDF 1 MB
Data Sheet | PDF | 5 versions
Data Sheet | PDF | 5 versions
Manuals and Support Information
Custom Protocol Selector
Generates customized, end-to-end instructions
All Illumina DNA RNA UD Indexes Support All Illumina DNA Prep with Enrichment Support
Illumina DNA Prep with Enrichment
A fast, integrated workflow for a wide range of applications providing targeted resequencing for custom panels, fixed panels, and whole-exome enrichment.
TruSeq Stranded Total RNA with Ribo-Zero Globin
Prepare whole-transcriptome sequencing libraries from blood-derived RNA with an efficient workflow that removes ribosomal RNA and globin mRNA in a single step.
TruSeq Stranded Total RNA
A robust, highly scalable whole-transcriptome analysis (RNA-Seq) solution for a variety of species and sample types, including human, mouse, and formalin-fixed, paraffin-embedded (FFPE) tissue.
AmpliSeq for Illumina Focus Panel
Targeted DNA and RNA research panel investigating 52 genes with known relevance to solid tumors.
AmpliSeq for Illumina Immune Response Panel
Targeted RNA expression panel investigating 395 genes involved in tumor-immune system interactions.
AmpliSeq for Illumina BRCA Panel
Targeted research panel investigating somatic and germline variants in BRCA1 and BRCA2.